Cellectar Biosciences Inc (CLRB): Next-Year EPS Estimate 52.12%
As of 2026-05-14, Cellectar Biosciences Inc (CLRB) has a next-year EPS growth estimate of 52.12%.
On 2026-05-14, analyst consensus for CLRB's next-year EPS growth shifted from 52.11% to 52.12% — a positive change of 0.01 percentage points. Current-year growth is projected at 74.61%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 52.12%
- EPS growth this year
- 74.61%
- EPS next quarter (est)
- -$0.59
- Last price
- $3.20
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-05-14 | 52.12% | 74.61% | -$0.59 | $3.20 |
| 2026-05-13 | 52.11% | 74.49% | -$1.89 | $2.96 |
| 2026-05-12 | 52.11% | 74.49% | -$1.89 | $2.92 |
| 2026-05-11 | 52.11% | 74.49% | -$1.89 | $3.06 |
| 2026-05-10 | 52.11% | 74.49% | -$1.89 | $3.10 |
| 2026-05-07 | 52.11% | 74.49% | -$1.89 | $3.30 |
| 2026-05-06 | 52.11% | 74.49% | -$1.89 | $3.53 |
| 2026-05-05 | 52.11% | 74.49% | -$1.89 | $3.18 |
Recent News
- BC-Most Active StocksAssociated Press
- Cellectar (CLRB) Phase 2b Data Shows Durable Responses in Waldenström MacroglobulinemiaInvestorsHub
- Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenstrom MacroglobulinemiaGlobeNewswire
- Cellectar Biosciences Announces Oversubscribed Financing Up to $140 MillionGlobeNewswire
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Cellectar Biosciences Inc's next-year EPS growth estimate?▾
As of 2026-05-14, Cellectar Biosciences Inc (CLRB) has a next-year EPS growth estimate of 52.12%, based on analyst consensus.
When was the latest EPS estimate revision for CLRB?▾
The most recent revision occurred on 2026-05-14, when analysts adjusted the next-year EPS growth estimate from 52.11% to 52.12%.
What sector and industry does Cellectar Biosciences Inc belong to?▾
Cellectar Biosciences Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. CLRB appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Cellectar Biosciences Inc (CLRB) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports